E
Eric J. Topol
Researcher at Scripps Health
Publications - 1406
Citations - 162373
Eric J. Topol is an academic researcher from Scripps Health. The author has contributed to research in topics: Myocardial infarction & Angioplasty. The author has an hindex of 193, co-authored 1373 publications receiving 151025 citations. Previous affiliations of Eric J. Topol include Loyola University Chicago & Cleveland Clinic.
Papers
More filters
Journal ArticleDOI
Time from symptom onset to treatment and outcomes after thrombolytic therapy
L. Kristin Newby,Wolfgang Rutsch,Robert M. Califf,Maarten L. Simoons,Philip E. Aylward,Paul W. Armstrong,Lynn H. Woodlief,Kerry L. Lee,Eric J. Topol,Frans Van de Werf +9 more
TL;DR: Earlier treatment resulted in better outcomes, regardless of thrombolytic strategy, in the international GUSTO-I trial.
Journal ArticleDOI
Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. TAMI Study Group.
Erik Magnus Ohman,Robert M. Califf,Eric J. Topol,Richard J. Candela,Charles W. Abbottsmith,Stephen G. Ellis,Kristina N. Sigmon,Dean J. Kereiakes,Barry S. George,Richard S. Stack +9 more
TL;DR: Reocclusion of the infarct-related artery after successful reperfusion is associated with substantial morbidity and mortality rates and new strategies in the postinfarction period need to be developed to prevent reocclusion.
Journal ArticleDOI
Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty.
James E. Tcheng,Stephen G. Ellis,Barry S. George,Dean J. Kereiakes,Neal S. Kleiman,J D Talley,Alice Wang,Harlan F. Weisman,Robert M. Califf,Eric J. Topol +9 more
TL;DR: The novel antiplatelet agent c7E3 Fab can be administered during PTCA in combination with aspirin and heparin and can be maintained for up to 24 hours, suggesting suppression of platelet activity is dose dependent.
Journal ArticleDOI
Can Mobile Health Technologies Transform Health Care
TL;DR: In this Viewpoint, examples of how mHealth technologies can transform health care by addressing inefficient practices and challenges faced by consumers and clinicians in the current system are offered.
Journal ArticleDOI
Platelet Glycoprotein IIb/IIIa Inhibitors Reduce Mortality in Diabetic Patients With Non–ST-Segment-Elevation Acute Coronary Syndromes
Marco Roffi,Derek P. Chew,Debabrata Mukherjee,Deepak L. Bhatt,Jennifer White,Christopher Heeschen,Christian W. Hamm,David J. Moliterno,Robert M. Califf,Harvey D. White,Neal S. Kleiman,Pierre Theroux,Eric J. Topol +12 more
TL;DR: A meta-analysis of the diabetic populations enrolled in the 6 large-scale platelet GP IIb/IIIa inhibitor ACS trials investigated whether diabetic patients with ACS derive particular benefit from platelet glycoprotein (GP) IIb-IIIa receptor inhibition.